Dutasteride: a novel dual inhibitor of 5α-reductase for benign prostatic hyperplasia

Author： Djavan Bob Milani Shirin Fong Yan Kit

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.6, Iss.2, 2005-02, pp. : 311-317

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Review on Steroidal 5-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia

Current Medicinal Chemistry, Vol. 18, Iss. 23, 2011-08 ,pp. : 3576-3589

Bentham Science Publishers

Access to resources Recommend Favorite

Comparison of α-Blocker Monotherapy and α-Blocker Plus 5α-Reductase Inhibitor Combination Therapy Based on Prostate Volume for Treatment of Benign Prostatic Hyperplasia

By Joo K-J Sung W-S Park S-H Yang W-J Kim T-H

The Journal of International Medical Research, Vol. 40, Iss. 3, 2012-05 ,pp. : 899-908

Field House Publishing

Access to resources Recommend Favorite

Dutasteride for the treatment of benign prostatic hyperplasia

By Wu Christopher Kapoor Anil

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 10, 2013-07 ,pp. : 1399-1408

Informa Healthcare

Access to resources Recommend Favorite

Dutasteride/Tamsulosin: In Benign Prostatic Hyperplasia

By Keating Gillian M.

Drugs & Aging, Vol. 29, Iss. 5, 2012-05 ,pp. : 405-419

Adis International

Access to resources Recommend Favorite

Inhibitors of 5-Reductase in the Treatment of Benign Prostatic Hyperplasia

Current Pharmaceutical Design, Vol. 12, Iss. 7, 2006-03 ,pp. : 775-783

Bentham Science Publishers

Access to resources Recommend Favorite